Increase in losses on equity-method investments
First written in FY2019-Q3. 3 of 11 entries say "Mitigated", first in FY2020-Q1. Latest entry: 2026-08-10.
The whole theme swung hardest in 2023: 19 of 68 companies on the "Worse" side.
24 other companies' latest entry also says "Other".
- 2026-08-10OtherEarnings presentation
「Ordinary income decreased by ¥1,415 million year on year, as the equity-method investment gain from Cellebrite declined by ¥1,463 million year on year to ¥364 million.」
The equity-method investment gain from Cellebrite was ¥364 million, down year on year. A review of the accounting treatment was cited as a factor behind the change. - FY2026Equity-method investment income increased significantlyAnnual report
「This was attributable to the recognition of ¥4,969 million in equity-method investment income.」
Cellebrite's equity-method investment income increased from ¥505 million in the previous year to ¥4,969 million, making it a major factor in the increase in ordinary income. - 2026-05-15MitigatedEarnings presentation
「Ordinary income increased by ¥4,423 million year on year, helped by the recognition of a ¥4,969 million equity-method investment gain from Cellebrite.」
The equity-method investment loss theme reversed over the full year, with a ¥4,969 million investment gain recognized as a driver of higher ordinary income. - FY2026-H1Continued recognition of equity-method investment incomeAnnual report
「As a result of recording ¥2,206 million in equity-method investment income」
After Cellebrite became an equity-method affiliate, ¥2,206 million in equity-method investment income was recorded. Investment gains and losses were zero in the same period of the previous year, resulting in equity-method income being recognized as a gain. - FY2025-H1MitigatedAnnual report
「Equity-method investment losses 4,498,420 ―」
The ¥4,498 million equity-method investment loss recorded in the same period of the previous year was not recorded in the current interim period. The reversal of Cellebrite's derivative valuation loss eliminated the loss burden on ordinary income. - FY2024-Q2WorsenedAnnual report
「The main factor was the recording of an equity-method investment loss of ¥4,498 million.」
Equity-method investment losses increased from ¥2,787 million in the previous quarter to ¥4,498 million in the cumulative second quarter. Valuation changes at Cellebrite became more pronounced through equity-method investment gains and losses. - FY2024-Q1WorsenedAnnual report
「This was primarily due to the Company recording an equity-method investment loss of ¥2,787 million, reflecting the impact of valuation losses on derivatives at Cellebrite.」
The Company recorded an equity-method investment loss of ¥2,787 million in the current quarter, compared with equity-method investment income in the previous fiscal year. Valuation changes in Cellebrite's derivatives were the main factor behind the ordinary loss. - FY2023Recognition of equity-method investment gainAnnual report
「Equity-method investment income 471,222」
Following the transfer of Cellebrite and other entities to equity-method affiliates, the Company recorded ¥471 million in equity-method investment income as non-operating income. - FY2020-Q2RestatedAnnual report
「Equity-method investment losses 148,879 ―」
Equity-method investment losses fell from ¥148.879 million in the same period of the previous year to zero in the current quarter, and no loss burden has continued to arise. - FY2020-Q1MitigatedAnnual report
「Equity-method investment losses 71,848 ―」
Equity-method investment losses fell from ¥71.848 million in the same period of the previous year to zero in the current quarter, eliminating the associated loss burden. - FY2019-Q3First statedAnnual report
「Equity-method investment losses 174,419 406,409」
The quarterly consolidated income statement reports that equity-method investment losses increased from ¥174.41 million in the same period of the previous year to ¥406.409 million.